N-[2-(aminocarbonyl)phenyl][1,1'-biphenyl]-4-carboxamide

APBC is a novel PD-L1 inhibitor, effectively interrupting the PD-1/PD-L1 interaction by directly binding to PD-L1, presenting the KD and IC50 values at low-micromolar level, displaying superior antitumor efficacy in hPD-L1 knock-in B16F10-bearing mouse model without the induction of observable liver toxicity.